Basit öğe kaydını göster

dc.contributor.authorCalguneri, M
dc.contributor.authorCobankara, V
dc.contributor.authorOzathi, D
dc.contributor.authorGuler, G
dc.contributor.authorApras, S
dc.contributor.authorPay, S
dc.contributor.authorKiraz, S
dc.contributor.authorErtenli, I
dc.contributor.authorOzturk, MA
dc.date.accessioned2019-12-10T11:14:29Z
dc.date.available2019-12-10T11:14:29Z
dc.date.issued2003
dc.identifier.issn0513-5796
dc.identifier.urihttps://doi.org/10.3349/ymj.2003.44.1.155
dc.identifier.urihttp://hdl.handle.net/11655/15154
dc.description.abstractGiant cell arteritis (GCA) is a common systemic vasculitis with an unknown etiology. It mainly affects people older than 50 years of age and often presents with symptoms such as headache, jaw claudication, visual loss, polymyalgia rheumatica and increased erythrocyte sedimentation rate (ESR). Established blindness is irreversible if the steroid treatment is not administered within a few days. Here, we report a case of GCA in a patient with a normal ESR whose left eye perceived just light at the initiation of treatment. Immediately prior to the combined treatment with high dose oral steroids and cyclophosphamide, the ESR level had increased to 80 mm/h and the vision improved after the combined treatment four months later.
dc.language.isoen
dc.publisherYonsei Univ Coll Medicine
dc.relation.isversionof10.3349/ymj.2003.44.1.155
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGeneral & Internal Medicine
dc.titleIs Visual Loss Due to Giant Cell Arteritis Reversible?
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalYonsei Medical Journal
dc.contributor.departmentİç hastalıkları
dc.identifier.volume44
dc.identifier.issue1
dc.identifier.startpage155
dc.identifier.endpage158
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster